Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Arrowhead Pharmaceuticals Inc. (ARWR) Insider Trading Activity
Healthcare • Biotechnology • 525 employees
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
Total Value
-$3,519,300.79
Total Shares
356,624
Average Trade Value
-$95,116.24
Most Active Insider
Anzalone Christopher Richard
Total Activity: $8,824,340
Largest Single Transaction
$3,005,006
by Anzalone Christopher Richard on Mar 3, 2025
30-Day Activity
2 Transactions
Volume: 0 shares
Value: $1,235,997
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Executive Officer
Director, Officer
|
Mar 4, 2025 | 133,333 | $2,269,328 | 3,773,802 (-3.5%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Mar 4, 2025 | 133,333 | $1,033,331 | 4,073,802 (+3.3%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Mar 3, 2025 | 166,667 | $3,005,006 | 3,907,135 (-4.3%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Mar 3, 2025 | 166,667 | $1,291,669 | 3,940,469 (+4.2%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Feb 7, 2025 | 9,550 | $191,955 | 3,773,802 (+0.3%) | Grant | |
|
Director
|
Feb 6, 2025 | 38,396 | $771,376 | 38,396 (+100.0%) | Grant | |
|
Director
|
Jan 23, 2025 | 959 | $20,139 | 35,781 (-2.7%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 7, 2025 | 8,000 | $157,600 | 465,433 (-1.7%) | Sale | |
|
COO and General Counsel
Officer
|
Jan 7, 2025 | 8,000 | $157,520 | 527,201 (-1.5%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 7, 2025 | 10,000 | $196,900 | 455,433 (-2.2%) | Sale | |
|
COO and General Counsel
Officer
|
Jan 6, 2025 | 19,658 | $387,066 | 544,727 (-3.6%) | Sale | |
|
Chief Discovery/trans Medicine
Officer
|
Jan 6, 2025 | 21,758 | $428,197 | 283,093 (-7.7%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 6, 2025 | 9,402 | $188,980 | 473,433 (-2.0%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 6, 2025 | 17,765 | $349,615 | 482,835 (-3.7%) | Sale | |
|
COO and General Counsel
Officer
|
Jan 6, 2025 | 9,526 | $191,473 | 535,201 (-1.8%) | Sale | |
|
Chief Discovery/trans Medicine
Officer
|
Jan 6, 2025 | 10,971 | $220,627 | 272,122 (-4.0%) | Sale | |
|
Chief Financial Officer
Officer
|
Jan 4, 2025 | 100,000 | $10,000 | 500,600 (+20.0%) | Grant | |
|
COO and General Counsel
Officer
|
Jan 4, 2025 | 100,000 | $10,000 | 564,385 (+17.7%) | Grant | |
|
Chief Discovery/trans Medicine
Officer
|
Jan 4, 2025 | 100,000 | $10,000 | 304,851 (+32.8%) | Grant | |
|
Chief Executive Officer
Director, Officer
|
Jan 2, 2025 | 11,520 | $219,456 | 3,764,252 (-0.3%) | Sale | |
|
Director
|
Dec 27, 2024 | 2,850 | $57,000 | 36,740 (-7.8%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Dec 23, 2024 | 12,563 | $246,109 | 3,775,772 (-0.3%) | Sale | |
|
Director
|
Dec 18, 2024 | 16,733 | $384,692 | 39,590 (+42.3%) | Grant | |
|
Director
|
Dec 18, 2024 | 16,733 | $384,692 | 37,944 (+44.1%) | Grant | |
|
Director
|
Dec 18, 2024 | 16,733 | $384,692 | 131,490 (+12.7%) | Grant | |
|
Chief Executive Officer
Director, Officer
|
Dec 18, 2024 | 5,799 | $128,274 | 3,688,335 (-0.2%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Dec 18, 2024 | 8,260 | $179,572 | 3,694,134 (-0.2%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Dec 18, 2024 | 12,653 | $259,640 | 3,702,394 (-0.3%) | Sale | |
|
Director
|
Dec 18, 2024 | 16,733 | $384,692 | 77,514 (+21.6%) | Grant | |
|
Director
|
Dec 18, 2024 | 16,733 | $384,692 | 57,111 (+29.3%) | Grant | |
|
Chief Executive Officer
Director, Officer
|
Dec 18, 2024 | 100,000 | $0 | 3,788,335 (+2.6%) | Grant | |
|
Director
|
Dec 18, 2024 | 16,733 | $384,692 | 47,163 (+35.5%) | Grant | |
|
Director
|
Dec 17, 2024 | 3,747 | $82,584 | 40,378 (-9.3%) | Sale | |
|
Director
|
Dec 17, 2024 | 547 | $12,056 | 124,167 (-0.4%) | Sale | |
|
Director
|
Dec 16, 2024 | 5,000 | $109,500 | 124,714 (-4.0%) | Sale | |
|
Director
|
Dec 16, 2024 | 3,748 | $82,081 | 44,125 (-8.5%) | Sale | |
|
Director
|
Dec 16, 2024 | 8,994 | $197,059 | 21,211 (-42.4%) | Sale |